Phaseline

Companies › Ottimo Pharma

Ottimo Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
OTP-01
Dual paratopic PD-1/VEGFR2 antibody
PDCD1, KDRPhase 1Advanced Solid TumorsDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07266428OTP-01Phase 1Advanced Solid TumorsOncologyDec 2028

Targets

PDCD1 (1) KDR (1)

Companies with the same targets

Akeso Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech AstraZeneca Shenyang Sunshine Pharmaceutical Hutchmed Regeneron Pharmaceuticals Merck & Co. (MSD) Ono Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.